Forty years have elapsed since the discovery of Marburg virus, and 130 years have elapsed since the discovery of Ebola virus. Filoviruses remained largely unknown until 1995, when Ebola virus re-emerged in Kikwit, Democratic Republic of the Congo (formerly Zaire). The fact that they are highly pathogenic for humans and nonhuman primates, to the point of being the subject of former biological weapons programs, makes Marburg and Ebola viruses feared pathogens worldwide today. Basic research on filovirus biology and pathogenesis has advanced over the past 10 years, leading to the development of reverse-genetics systems, potential treatment strategies, and vaccine candidates. However, because the animal reservoir is still unknown, the clinical course of human infections is not yet adequately understood, and knowledge concerning the immunologic response is incomplete, there is still a long way to go.
In September of 2006, a global symposium on recent advances and future challenges in filovirus research was held in Winnipeg, Manitoba, Canada. The collection of articles in this special supplement of the Journal of Infectious Diseases focuses on Ebola and Marburg viruses, with an emphasis on work that was presented at the Winnipeg meeting. These articles bring us up to date in our understanding of the mechanisms of how filoviruses emerge and re-emerge, the molecular mechanisms of how these viruses replicate and cause disease, and, finally, on the recent progress that has been made in diagnosing filoviral hemorrhagic fever and in developing vaccines and therapies against these lethal microbes. From a public health perspective, among the most important advances are usable rapid and sensitive diagnostics and the development of promising treatment strategies and different vaccine platforms that have demonstrated efficacy in nonhuman primates against Ebola virus, Marburg virus, or both. Because outbreaks of Ebola and Marburg hemorrhagic fever are rare and, to date, restricted to parts of Africa, finding a suitable population in which to systematically evaluate the utility of any countermeasure presents a formidable obstacle and a huge challenge. Studies suggesting that bats are a potential reservoir host for filoviruses are particularly exciting, although this avenue of study needs further confirmation.
Scientific highlights from the meeting and contained in this supplement include detailed elucidation of filovirus biology, involving concepts based on work using recently developed reverse-genetics systems. These systems, which are available in several laboratories, will be instrumental in further dissecting the pathogenesis of filoviral hemorrhagic fever. Finally, this supplement also contains articles that discuss experiences and challenges in Ebola and Marburg disease case and outbreak management that will lead to improved responses in the future. In the past, efforts to study filoviruses have been slowed because these agents require special biocontainment laboratories to safely conduct research. The field of emerging pathogens has changed markedly since Karl Johnson spearheaded the effort to adapt the principles of biosafety level 4 biocontainment, originally developed by biodefense workers at Fort Detrick, into the first fully integrated space suit laboratory in 1978. At the time, the global importance of rare exotic pathogens, such as Ebola and Marburg viruses, and the need for high-level containment were not as apparent as they are today. Fortunately, these early efforts by Johnson and many others to promote and develop these facilities laid the foundation for a landscape that would change. Indeed, the increase in occurrences of outbreaks of emerging and re-emerging viruses over the past decade, coupled with the tragic terrorist events of 11 September 2001, have led to an increased investment in basic research and to the construction of a network of biocontainment laboratories (table 1). 
NOTE.
The table is not intended to serve as a definitive source on the current status of biosafety level 4 (BSL4) facilities, because it is recognized that this is a rapidly changing area. It refers to laboratories that are using or are planning to use 1-piece positive-pressure suits ("space suits") and does not reflect laboratories that have or plan to have class III biological safety cabinets ("glove boxes" As a result of an influx of new scientists who will be studying filoviruses, and with increasing recent interest in Ebola and Marburg viruses, a series of future international meetings is being organized to bring researchers working on these pathogens together. Meetings planned include conferences in Libreville, Gabon, in 2008 and in Tokyo, Japan, in 2010. These symposia will seek to build on the experience of previous events held in Marburg, Germany, in 2000; in Bethesda, Maryland, in 2003; and in Winnipeg, Canada, in 2006 . The primary objectives of these meetings will be to provide opportunities for researchers working on filoviruses to present their work to peers, foster new collaborations, and facilitate efforts to develop effective countermeasures against these pathogens.
